TGFB1 and neoplasm: Inhibition of IDO, PGE2, A2aR, and TGFβ, coupled with factors that enhance tumor perfusion, such as metronomic chemotherapy, which also increases NK cell recruitment into tumors, may enhance NK-mediated immunotherapies.